Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
Roberto Felice CaporaliYannick AllanoreRieke E AltenBernard G CombePatrick DurezFlorenzo IannoneMike T NurmohamedSang Joon LeeTaek Sang KwonJean Soo ChoiGahee ParkDae Hyun YooPublished in: Expert review of clinical immunology (2020)
CT-P13 SC offers an improved or similar benefit-to-harm ratio compared with infliximab (intravenous) and adalimumab/etanercept, for the treatment of moderate-to-severe RA.
Keyphrases
- rheumatoid arthritis
- ulcerative colitis
- juvenile idiopathic arthritis
- ankylosing spondylitis
- disease activity
- high dose
- rheumatoid arthritis patients
- computed tomography
- interstitial lung disease
- high intensity
- image quality
- contrast enhanced
- positron emission tomography
- systemic sclerosis
- low dose
- smoking cessation
- patients with inflammatory bowel disease